 NEW YORK, Sept. 27, 2021 GLOBE NEWSWIRE -- Anavex Life Sciences Corp. Anavex or the Company Nasdaq: AVXL, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system CNS disorders, today announced that effective as of market open today, September 27, 2021, its shares of common stock have been approved for uplisting to the NASDAQ Global Select Market and will continue trading under its current ticker symbol AVXL. 